Optical Imaging for Determination of Apoptosis Medicated Therapeutic Efficacy

Kaijun Zhang
*Thomas Jefferson University, Kaijun.Zhang@jefferson.edu*

Bishnuhari Paudyal
*Thomas Jefferson University, Bishnuhari.Paudyal@jefferson.edu*

Neil Mehta
*Thomas Jefferson University, Neil.Mehta@jefferson.edu*

Brian Gray
*Molecular Targeting Technologies, Inc.*

Koon Y. Pak
*Molecular Targeting Technologies, Inc.*

*See next page for additional authors*

Let us know how access to this document benefits you

Follow this and additional works at: [https://jdc.jefferson.edu/radiologyfp](https://jdc.jefferson.edu/radiologyfp)

Part of the [Medical Molecular Biology Commons](https://jdc.jefferson.edu/medicalmolbiol) and the [Radiology Commons](https://jdc.jefferson.edu/radiology)

**Recommended Citation**

Zhang, Kaijun; Paudyal, Bishnuhari; Mehta, Neil; Gray, Brian; Pak, Koon Y.; Wickstrom, Eric; and Thakur, Mathew L, "Optical Imaging for Determination of Apoptosis Medicated Therapeutic Efficacy" (2012). *Department of Radiology Faculty Papers*. Paper 19.

[https://jdc.jefferson.edu/radiologyfp/19](https://jdc.jefferson.edu/radiologyfp/19)

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University’s Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Radiology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.
OPTICAL IMAGING FOR DETERMINATION OF APOPTOSIS MEDICATED THERAPEUTIC EFFICACY

K Zhang, PhD¹, B. Paudyal, PhD¹, N. Mehta¹, B Gray, PhD⁴, C Pak, PhD⁴, E Wickstrom, PhD²,³, M. Thakur, PhD¹,³
Departments of: Radiology¹, Biochem. & Mol. Biol.², Kimmel Cancer Center³, Thomas Jefferson University, Philadelphia, PA; Molecular Targeting Technologies, Inc.⁴

West Chester, PA

Results:
T/M ratios for PSVue®794 were 200% times higher than for PSVue®643 (P < 0.05). Both probes showed 25%-30% increased T/M ratios post DOX treatment, (P < 0.05) indicative of enhanced apoptosis. With PSVue®643 tumor intensity declined over time, but increased for intestine. With PSVue®794 tumor intensity and T/M ratios increased as a function of time, with a decreased M/O ratios for all organs.

Methods:
Two NIR fluorophores linked bis-zinc (II) dipicolylamine coordination complexes, PSVue®643 and PSVue®794, served as the probes. Athymic nude mice bearing human BC tumors BT474, received 16.5 µg of one of the NIR probes i.v. before and after 40 µg of doxorubicin (DOX) given once I.P. OI was performed up to 24 hrs post injection (PSVue®643; Abs. 643 nm; Em. 658 nm; PSVue®794; Abs. 794 nm; Em. 810 nm). Tumor/muscle (T/M) and organ/muscle (O/M) ratios were calculated and plotted.

Conclusion:
OI of apoptotic BC cells mediated by DOX treatment permits to determine the effectiveness of DOX within 24 hrs. These results are consistent with those in another investigation in which F-18-FDG was used to monitor diminished metabolic activity following DOX treatment. PSVue®794 which eliminates radiation burden to normal organs is a preferable NIR fluorophore for determination of therapeutic effectiveness of BC by OI.

Support: NIH 1S10 RR026678-01 (MLT).